Amarin Co. plc (AMRN) Short Interest Up 13.6% in February

Amarin Co. plc (NASDAQ:AMRN) saw a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 17,514,524 shares, an increase of 13.6% from the February 15th total of 15,412,976 shares. Currently, 6.1% of the shares of the stock are sold short. Based on an average trading volume of 10,037,142 shares, the short-interest ratio is currently 1.7 days.

In related news, General Counsel Joseph T. Kennedy sold 1,040,194 shares of the business’s stock in a transaction that occurred on Thursday, January 24th. The shares were sold at an average price of $17.77, for a total transaction of $18,484,247.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Joseph S. Zakrzewski sold 526,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 2nd. The shares were sold at an average price of $13.07, for a total transaction of $6,881,355.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 2,841,072 shares of company stock valued at $49,748,088. Insiders own 4.08% of the company’s stock.

Several hedge funds have recently made changes to their positions in AMRN. Benjamin F. Edwards & Company Inc. acquired a new stake in shares of Amarin during the 4th quarter worth approximately $34,000. Neuburgh Advisers LLC acquired a new stake in shares of Amarin during the 4th quarter worth approximately $36,000. Global Retirement Partners LLC grew its position in shares of Amarin by 266.3% during the 4th quarter. Global Retirement Partners LLC now owns 2,612 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 1,899 shares during the period. Lindbrook Capital LLC acquired a new stake in shares of Amarin during the 4th quarter worth approximately $40,000. Finally, Financial Advocates Investment Management grew its position in shares of Amarin by 45.0% during the 4th quarter. Financial Advocates Investment Management now owns 29,000 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 9,000 shares during the period. 48.30% of the stock is owned by institutional investors.

A number of brokerages have recently commented on AMRN. BidaskClub raised shares of Amarin from a “hold” rating to a “buy” rating in a research report on Wednesday, February 27th. Cantor Fitzgerald reiterated a “buy” rating and issued a $35.00 price objective on shares of Amarin in a report on Friday, December 7th. Zacks Investment Research upgraded shares of Amarin from a “sell” rating to a “hold” rating in a report on Wednesday, January 23rd. HC Wainwright restated a “buy” rating and issued a $51.00 price target on shares of Amarin in a research note on Thursday, January 17th. Finally, Citigroup decreased their price target on shares of Amarin to $20.00 in a research note on Tuesday, January 8th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $33.20.

Amarin stock opened at $20.57 on Friday. The company has a market cap of $6.61 billion, a price-to-earnings ratio of -52.74 and a beta of 1.29. Amarin has a 52-week low of $2.35 and a 52-week high of $23.33. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.40 and a quick ratio of 2.04.

Amarin (NASDAQ:AMRN) last announced its quarterly earnings data on Wednesday, February 27th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.03). The firm had revenue of $77.30 million for the quarter, compared to the consensus estimate of $73.87 million. The firm’s revenue for the quarter was up 43.4% on a year-over-year basis. During the same period last year, the business posted ($0.08) earnings per share. Analysts forecast that Amarin will post -0.17 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This article was originally published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.thelincolnianonline.com/2019/03/15/amarin-co-plc-amrn-short-interest-up-13-6-in-february.html.

About Amarin

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Featured Article: Cryptocurrencies

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply